Download PDF
LOUISVILLE, CO -- (Marketwired) -- 01/05/15 -- AntriaBio, Inc. ("Company") (OTCQB: ANTB), a biopharmaceutical corporation focused on developing novel extended release therapies, announced today that it has successfully raised approximately $7 million in a private placement transaction. At $1.85 per unit, institutions and accredited investors were issued one share of common stock and one warrant exercisable for three years at $2.50 for one share of common stock. Notably, the Company was successful in raising over $18 million through equity financings in 2014.
AntriaBio will use the proceeds from its most recent financing for general corporate purposes including the production of cGMP material and initiation of Phase 1 clinical studies for AB101, a basal insulin with potential for once-weekly dosing for patients with type 1 and type 2 diabetes.
Nevan Elam, Chairman and Chief Executive Officer stated, "Our fundraising efforts in 2014 were instrumental in advancing our clinical program for AB101. The confidence that our investors have shown in us is a testament to our extended release platform and the potential of AB101 to transform the $10 billion basal insulin market."
The securities sold in the financing have not been registered under the United States Securities Act of 1933, as amended ("Securities Act"), and may not be offered or sold in the US absent registration or an applicable exemption from registration requirements. As part of the financing, the Company has agreed to file a resale registration statement on Form S-1 with the United States Securities and Exchange Commission within 90 days of the closing of the financing for purposes of registering the resale of the shares of common stock issued or issuable in connection with the financing.
This press release is being issued pursuant to Rule 135c under the Securities Act and does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state. Any offering of the securities under the resale registration statement will only be by means of a prospectus.
About AntriaBio, Inc.
AntriaBio is a biopharmaceutical company that develops novel extended release therapies by combining proprietary formulation and manufacturing capabilities with well-known molecules to significantly improve standards of care. For more information visit: www.antriabio.com.
http://www.antriabio.com/news/press-releases/detail/204/antriabio-announces-7-million-private-placement
Recent RZLT News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/24/2024 09:14:46 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/19/2024 08:23:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/19/2024 08:09:55 PM
- Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 09/19/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/09/2024 11:30:26 AM
- FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study • GlobeNewswire Inc. • 09/09/2024 11:30:00 AM
- Rezolute to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 08/27/2024 12:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/15/2024 04:15:11 AM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 08/10/2024 01:47:17 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 08/05/2024 09:00:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/05/2024 11:30:33 AM
- Rezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism • GlobeNewswire Inc. • 08/05/2024 11:30:00 AM
- Rezolute to Participate in the BTIG Virtual Biotechnology Conference • GlobeNewswire Inc. • 07/31/2024 12:00:00 PM
- Rezolute Announces Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement • GlobeNewswire Inc. • 06/27/2024 12:00:00 PM
- Rezolute Announces Closing of Public Offering with Approximately $60M in Gross Proceeds • GlobeNewswire Inc. • 06/24/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 08:51:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 06/14/2024 08:49:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 04:51:20 PM
- Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants • GlobeNewswire Inc. • 06/14/2024 03:30:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 06/13/2024 09:25:55 PM
- Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants • GlobeNewswire Inc. • 06/13/2024 08:01:00 PM
- Rezolute to Participate in the Jefferies Global Healthcare Conference • GlobeNewswire Inc. • 05/30/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/28/2024 06:56:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/24/2024 06:37:52 PM
- Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME) • GlobeNewswire Inc. • 05/21/2024 08:05:00 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM